{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:33:22Z","timestamp":1792218802098,"version":"4.4.0"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T00:00:00Z","timestamp":1723248000000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Bowel urgency is a highly disruptive and bothersome symptom experienced by patients with inflammatory bowel diseases (IBD), (ulcerative colitis [UC], and Crohn\u2019s disease [CD]). However, the burden of bowel urgency among patients with varying experiences in targeted treatment has not been consistently assessed. This real-world study explored the clinical and health-related quality of life burden of bowel urgency among patients with IBD with differing treatment experiences.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This cross-sectional survey included gastroenterologists and their patients with IBD across France, Germany, Italy, Spain, the United Kingdom, and the United States treated for over 3 months. Physicians provided patient demographics, clinical characteristics, and treatment history. Patients reported their health-related quality of life and work productivity. Patients with UC and CD were analyzed separately and stratified into 3 groups: Targeted therapy na\u00efve, those receiving their first-line targeted therapy, and targeted therapy experienced.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>This study found that 17%-26% of UC and 13%-17% of CD patients experienced persistent bowel urgency, irrespective of receiving conventional or targeted therapy. Moreover, patients with bowel urgency experienced an increased clinical and health-related quality of life burden compared to patients without bowel urgency, which physicians most commonly regarded as one of the most difficult symptoms to treat, with the burden remaining substantial irrespective of their treatment experience.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Despite several current treatment options, new therapeutic strategies are necessary to provide relief from bowel urgency, one of the most challenging symptoms for people living with IBD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/crocol\/otae047","type":"journal-article","created":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T02:26:07Z","timestamp":1723170367000},"source":"Crossref","is-referenced-by-count":7,"title":["Burden of Bowel Urgency in Patients With Ulcerative Colitis and Crohn\u2019s Disease: A Real-World Global Study"],"prefix":"10.1093","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8556-8433","authenticated-orcid":false,"given":"Raja","family":"Atreya","sequence":"first","affiliation":[{"name":"Medical Department 1, University Hospital Erlangen, Friedrich Alexander University Erlangen-N\u00fcrnberg , Erlangen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Redondo","sequence":"additional","affiliation":[{"name":"Medical Affairs, Eli Lilly and Company , Lisbon , Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0193-4879","authenticated-orcid":false,"given":"Petra","family":"Streit","sequence":"additional","affiliation":[{"name":"Global New Product Planning,\u00a0Eli Lilly and Company , Vernier , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marijana","family":"Protic","sequence":"additional","affiliation":[{"name":"Medical Affairs, Eli Lilly and Company , Vernier , Switzerland \u00a0"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8475-0260","authenticated-orcid":false,"given":"Susanne","family":"Hartz","sequence":"additional","affiliation":[{"name":"Value, Evidence and Outcomes \u2013 International,\u00a0Eli Lilly and Company , Bracknell , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6966-4644","authenticated-orcid":false,"given":"Gamze","family":"Gurses","sequence":"additional","affiliation":[{"name":"Reimbursement Access,\u00a0Eli Lilly and Company , Istanbul , Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8379-4381","authenticated-orcid":false,"given":"Hannah","family":"Knight","sequence":"additional","affiliation":[{"name":"Autoimmune Franchise, Adelphi Real World , Bollington , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5604-1360","authenticated-orcid":false,"given":"Sophie","family":"Barlow","sequence":"additional","affiliation":[{"name":"Statistics & Data Analytics , Adelphi Real World, Bollington , UK \u00a0"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2855-297X","authenticated-orcid":false,"given":"Niamh","family":"Harvey","sequence":"additional","affiliation":[{"name":"Autoimmune Franchise, Adelphi Real World , Bollington , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8412-9175","authenticated-orcid":false,"given":"Theresa","family":"Hunter Gibble","sequence":"additional","affiliation":[{"name":"Value, Evidence and Outcomes, Eli Lilly and Company , Indianapolis , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,10]]},"reference":[{"issue":"10080","key":"2024091509002191800_CIT0001","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Unagro","year":"2016","journal-title":"Lancet."},{"issue":"10080","key":"2024091509002191800_CIT0002","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","article-title":"Crohn\u2019s disease","volume":"389","author":"Torres","year":"2017","journal-title":"Lancet."},{"issue":"10114","key":"2024091509002191800_CIT0003","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet."},{"issue":"3","key":"2024091509002191800_CIT0004","doi-asserted-by":"crossref","first-page":"otab046","DOI":"10.1093\/crocol\/otab046","article-title":"Prevalence and factors associated with fecal urgency among patients with ulcerative colitis and crohn\u2019s disease in the study of a prospective adult research cohort with inflammatory bowel disease","volume":"3","author":"Dawwas","year":"2021","journal-title":"Crohns Colitis 360."},{"issue":"3","key":"2024091509002191800_CIT0005","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2036.2004.02028.x","article-title":"A new questionnaire for constipation and faecal incontinence","volume":"20","author":"Bharucha","year":"2004","journal-title":"Aliment Pharmacol Ther."},{"issue":"suppl_1","key":"2024091509002191800_CIT0006","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1093\/ibd\/izac015.127","article-title":"Communicating Needs and Features of IBD Experiences (CONFIDE) survey: burden and impact of bowel urgency on patients with moderate to severe ulcerative colitis","volume":"28","author":"Schreiber","year":"2022","journal-title":"Inflamm Bowel Dis."},{"issue":"3","key":"2024091509002191800_CIT0007","doi-asserted-by":"crossref","first-page":"otac016","DOI":"10.1093\/crocol\/otac016","article-title":"Impact of bowel urgency on quality of life and clinical outcomes in patients with ulcerative colitis","volume":"4","author":"Dubinsky","year":"2022","journal-title":"Crohns Colitis 360."},{"key":"2024091509002191800_CIT0008","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/1471-230X-12-108","article-title":"Perception gaps between patients with ulcerative colitis and healthcare professionals: an online survey","volume":"12","author":"Schreiber","year":"2012","journal-title":"BMC Gastroenterol."},{"issue":"9","key":"2024091509002191800_CIT0009","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1097\/MEG.0000000000000658","article-title":"Perception of disease burden and treatment satisfaction in patients with ulcerative colitis from outpatient clinics in Spain: UC-LIFE survey","volume":"28","author":"Carpio","year":"2016","journal-title":"Eur J Gastroenterol Hepatol."},{"issue":"2","key":"2024091509002191800_CIT0010","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.dld.2016.09.009","article-title":"Patient preferences for inflammatory bowel disease treatment objectives","volume":"49","author":"Casellas","year":"2017","journal-title":"Dig Liver Dis."},{"issue":"12","key":"2024091509002191800_CIT0011","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1007\/s11136-020-02606-2","article-title":"An assessment of symptom burden in inflammatory bowel diseases to develop a patient preference-weighted symptom score","volume":"29","author":"van Deen","year":"2020","journal-title":"Qual Life Res."},{"issue":"3","key":"2024091509002191800_CIT0012","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/ecco-jcc\/jjv218","article-title":"Self-reported symptom burden in individuals with inflammatory bowel disease","volume":"10","author":"Farrell","year":"2015","journal-title":"J Crohns Colitis."},{"key":"2024091509002191800_CIT0013","doi-asserted-by":"crossref","first-page":"i302","DOI":"10.1093\/ecco-jcc\/jjab232.388","article-title":"P261 Burden of bowel urgency across specific treatment groups among Ulcerative Colitis patients \u2013 real world global study analyses","volume":"16","author":"Atreya","year":"2022","journal-title":"J Crohns Colitis."},{"issue":"12","key":"2024091509002191800_CIT0014","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1093\/ibd\/izab006","article-title":"International perspectives on management of inflammatory bowel disease: opinion differences and similarities between patients and physicians from the IBD GAPPS survey","volume":"27","author":"Rubin","year":"2021","journal-title":"Inflamm Bowel Dis."},{"issue":"3","key":"2024091509002191800_CIT0015","doi-asserted-by":"crossref","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG Clinical Guideline: Ulcerative Colitis in Adults","volume":"114","author":"Rubin","year":"2019","journal-title":"Am J Gastroenterol."},{"issue":"1","key":"2024091509002191800_CIT0016","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","article-title":"3rd European evidence-based consensus on the diagnosis and management of Crohn\u2019s disease 2016: part 1: diagnosis and medical management","volume":"11","author":"Gomoll\u00f3n","year":"2016","journal-title":"J Crohns Colitis."},{"issue":"7","key":"2024091509002191800_CIT0017","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/ecco-jcc\/jjx009","article-title":"Third European evidence-based consensus on diagnosis and management of ulcerative colitis. part 2: current management","volume":"11","author":"Harbord","year":"2017","journal-title":"J Crohns Colitis."},{"issue":"4","key":"2024091509002191800_CIT0018","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1053\/j.gastro.2022.06.068","article-title":"CORE-IBD: a multidisciplinary international consensus initiative to develop a core outcome set for randomized controlled trials in inflammatory bowel disease","volume":"163","author":"Ma","year":"2022","journal-title":"Gastroenterology."},{"issue":"1","key":"2024091509002191800_CIT0019","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s41687-022-00439-w","article-title":"Incorporating patient experience into drug development for ulcerative colitis: development of the Urgency Numeric Rating Scale, a patient-reported outcome measure to assess bowel urgency in adults","volume":"6","author":"Dubinsky","year":"2022","journal-title":"J Patient Rep Outcomes"},{"issue":"2","key":"2024091509002191800_CIT0020","doi-asserted-by":"crossref","first-page":"otab013","DOI":"10.1093\/crocol\/otab013","article-title":"Fecal incontinence in inflammatory bowel disease","volume":"3","author":"Kamal","year":"2021","journal-title":"Crohns Colitis 360."},{"issue":"1","key":"2024091509002191800_CIT0021","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO guidelines on therapeutics in crohn\u2019s disease: medical treatment","volume":"14","author":"Torres","year":"2019","journal-title":"J Crohns Colitis."},{"issue":"1","key":"2024091509002191800_CIT0022","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2021","journal-title":"J Crohns Colitis."},{"key":"2024091509002191800_CIT0023","doi-asserted-by":"crossref","first-page":"ii54","DOI":"10.1093\/ecco-jcc\/jjac007","article-title":"IL-23 Blockade in Anti-TNF Refractory IBD: from mechanisms to clinical reality","volume":"16","author":"Atreya","year":"2022","journal-title":"J Crohns Colitis."},{"key":"2024091509002191800_CIT0024","doi-asserted-by":"crossref","first-page":"17562848211006669","DOI":"10.1177\/17562848211006669","article-title":"Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches","volume":"14","author":"Privitera","year":"2021","journal-title":"Therap Adv Gastroenterol"},{"key":"2024091509002191800_CIT0025","doi-asserted-by":"crossref","first-page":"17562848211065329","DOI":"10.1177\/17562848211065329","article-title":"Optimizing biologic therapy in inflammatory bowel disease: a Delphi consensus in the United Arab Emirates","volume":"14","author":"Annese","year":"2021","journal-title":"Therap Adv Gastroenterol"},{"issue":"11","key":"2024091509002191800_CIT0026","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1185\/03007990802457040","article-title":"Real-world physician and patient behaviour across countries: Disease-Specific Programmes - a means to understand","volume":"24","author":"Anderson","year":"2008","journal-title":"Curr Med Res Opin."},{"issue":"6","key":"2024091509002191800_CIT0027","doi-asserted-by":"crossref","first-page":"e010352","DOI":"10.1136\/bmjopen-2015-010352","article-title":"Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the Disease Specific Programme","volume":"6","author":"Babineaux","year":"2016","journal-title":"BMJ Open"},{"issue":"9","key":"2024091509002191800_CIT0028","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2147\/DMSO.S120101","article-title":"Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015","volume":"Volume 9","author":"Higgins","year":"2016","journal-title":"Diabetes Metab Syndr Obes"},{"key":"2024091509002191800_CIT0029","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut."},{"issue":"1","key":"2024091509002191800_CIT0030","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/ibd.21400","article-title":"Short CDAI: development and validation of a shortened and simplified Crohn\u2019s disease activity index","volume":"17","author":"Thia","year":"2011","journal-title":"Inflamm Bowel Dis."},{"issue":"3","key":"2024091509002191800_CIT0031","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol - a new facility for the measurement of health-related quality of life","volume":"16","author":"The EuroQol Group","year":"1990","journal-title":"Health Policy"},{"issue":"8","key":"2024091509002191800_CIT0032","first-page":"1571","article-title":"The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn\u2019s Relapse Prevention Trial","volume":"91","author":"Irvine","year":"1996","journal-title":"Am J Gastroenterol."},{"issue":"5","key":"2024091509002191800_CIT0033","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a work productivity and activity impairment instrument","volume":"4","author":"Reilly","year":"1993","journal-title":"PharmacoEcon."},{"key":"2024091509002191800_CIT0034","year":"2021"},{"key":"2024091509002191800_CIT0035","year":"2022"},{"key":"2024091509002191800_CIT0036","author":"US Department of Health and Human Services","year":"2003"},{"key":"2024091509002191800_CIT0037","author":"Health Information Technology","year":"2009"},{"issue":"21","key":"2024091509002191800_CIT0038","doi-asserted-by":"crossref","first-page":"11322","DOI":"10.3390\/ijms222111322","article-title":"The era of janus kinase inhibitors for inflammatory bowel disease treatment","volume":"22","author":"Kim","year":"2021","journal-title":"Int J Mol Sci ."},{"issue":"2","key":"2024091509002191800_CIT0039","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1053\/j.gastro.2021.10.050","article-title":"Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with Crohn\u2019s disease","volume":"162","author":"Sands","year":"2022","journal-title":"Gastroenterology."},{"issue":"20","key":"2024091509002191800_CIT0040","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12955-022-01975-1","article-title":"Development and content validation of patient-reported outcomes tools for ulcerative colitis and Crohn\u2019s disease in adults with moderate-to-severe disease","volume":"20","author":"Nag","year":"2022","journal-title":"Health Qual Life Outcomes"},{"issue":"8","key":"2024091509002191800_CIT0041","doi-asserted-by":"crossref","first-page":"682","DOI":"10.5152\/tjg.2022.21375","article-title":"Usefulness of examining various patient-reported outcomes in predicting endoscopic mucosal healing in ulcerative colitis","volume":"33","author":"Moon","year":"2022","journal-title":"Turk J Gastroenterol."},{"issue":"5","key":"2024091509002191800_CIT0042","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology."}],"container-title":["Crohn's &amp; Colitis 360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/advance-article-pdf\/doi\/10.1093\/crocol\/otae047\/58793063\/otae047.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/advance-article-pdf\/doi\/10.1093\/crocol\/otae047\/59124696\/otae047.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/advance-article-pdf\/doi\/10.1093\/crocol\/otae047\/59124696\/otae047.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T09:00:45Z","timestamp":1726390845000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article\/doi\/10.1093\/crocol\/otae047\/7731314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,1]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/crocol\/otae047","relation":{},"ISSN":["2631-827X"],"issn-type":[{"value":"2631-827X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,7]]},"published":{"date-parts":[[2024,7,1]]},"article-number":"otae047"}}